Loading
Life sciences · Journal article
Zentralblatt Für Chirurgie - Zeitschrift Für Allgemeine Viszeral- Thorax- Und Gefäßchirurgie · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have evolved rapidly from an antidiabetic drug class into one of the most influential pharmacological groups in internal medicine. The approved agents - semaglutide, liraglutide and the dual GIP/GLP-1 agonist tirzepatide - achieve weight reductions of up to 22% of body weight. The close pathophysiological link between obesity, metabolic syndrome and urological-andrological disease creates direct clinical relevance for urology.This narrative review summarises a systematic PubMed search (2020-2026) covering erectile dysfunction, hypogonadism, male fertility, nephroprotection, prostate cancer, lower urinary tract symptoms and perioperative considerations in the context of GLP-1 RA therapy.GLP-1 RAs show clinically relevant effects in several urological domains: increase in total testosterone and improvement in erectile function in men with obesity-related hypogonadism, nephroprotection with reduction of albuminuria and slowing of eGFR decline, signals of reduced prostate cancer risk in epidemiological studies, and indirect benefit for stress incontinence and overactive bladder via weight loss. At the same time, clinically relevant warning signals exist: a 4.5-fold increased risk of new-onset erectile dysfunction in non-diabetic obese men on semaglutide, novel urological adverse effects in case reports, perioperative aspiration risk through delayed gastric emptying, and a near-complete absence of data in women.GLP-1 RAs represent both a therapeutic opportunity and a clinical challenge for urologists. Systematic andrological and nephrological monitoring as well as proactive patient education on urogenital and perioperative implications is recommended. Prospective controlled trials with urological endpoints are needed.